Listed

Compass Therapeutics, Inc.: Form 10-Q for the period ended Sep 30, 2019

Filed with the SEC on Nov 13, 2019 and accepted by EDGAR at Nov 13, 2019, 17:25 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2019-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Operating income3 months2019-07-01 to 2019-09-30−$7.2kus-gaap:OperatingIncomeLoss
Operating income6 months2019-04-01 to 2019-09-30−$17.5kus-gaap:OperatingIncomeLoss
Interest expense3 months2019-07-01 to 2019-09-30$1.3kus-gaap:InterestExpense
Interest expense6 months2019-04-01 to 2019-09-30$2.4kus-gaap:InterestExpense
Net income3 months2019-07-01 to 2019-09-30−$8.4kus-gaap:NetIncomeLoss
Net income6 months2019-04-01 to 2019-09-30−$19.9kus-gaap:NetIncomeLoss
Diluted EPS3 months2019-07-01 to 2019-09-30$0.00us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS6 months2019-04-01 to 2019-09-30$0.00us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow6 months2019-04-01 to 2019-09-30−$17.5kus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2019-09-30$882us-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2019-09-30$882us-gaap:AssetsCurrent
Total assetsAt period end2019-09-30$882us-gaap:Assets
Current liabilitiesAt period end2019-09-30$91.3kus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2019-09-30$91.3kus-gaap:Liabilities
Shareholders' equityAt period end2019-09-30−$90.5kus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001213900-19-023231. Last ingested by Listed: Nov 10, 2026, 16:45 ET. Listed shows no prices and gives no investment advice.